AstraZeneca (LON:AZN) and GlaxoSmithKline (LON:GSK) are the two pharmaceutical giants of the FTSE 100. They are also both high yield dividend stocks with yields of more than 4%.
Another notable fact is that both companies have been long-term holdings of a certain Mr Neil Woodford. But no more.
Following a 15-year holding period, Woodford sold Glaxo earlier this year, partly due to fears about the dividend's sustainability. Meanwhile, AstraZeneca remains in Woodford's equity income portfolio with a hefty 8% weighting.
So is AstraZeneca really a better bet than Glaxo? Let's take a look…
by Robert Stephens| Equities| 2 mins. to read Recovery stocks can be among the most profitable investments. One reason for this is that the market usually expects disappointing financial performance from them, which generally means low valuations.
by Evil Knievil| Evil Diaries| 1 mins. to read It's a wungermaul life: I did not realise this until listening to the tennis yesterday. A wungermaul arises where each player has won one game. My pick, Venus Williams, is still there.
Material contained within Master Investor Magazine and its website is for general information purposes only and is not intended to be relied upon by individual readers in making (or refraining from making) any specific investment decisions. Master Investor Ltd. does not accept any liability for any losses suffered by any user as a result or any such decision.
Ingen kommentarer:
Send en kommentar